Virus Propagation and Cell-Based Colorimetric Quantification

Jia-Yi Tan; Jo-Ern Wong; Nurhafiza Zainal; Sazaly AbuBakar; Kim-Kee Tan

doi:10.3791/64578

JoVE Journal > Immunology and Infection

Inmunología y contagio

Virus Propagation and Cell-Based Colorimetric Quantification

Published: April 07, 2023

doi:

10.3791/64578

Jia-Yi Tan¹, Jo-Ern Wong¹, Nurhafiza Zainal², Sazaly AbuBakar¹, Kim-Kee Tan¹

¹Tropical Infectious Diseases Research and Education Centre (TIDREC), Higher Institution Center of Excellence (HICoE),Universiti Malaya, ²Department of Medical Microbiology, Faculty of Medicine,Universiti Malaya

Summary

The present protocol describes the propagation of Zika virus (ZIKV) in Vero African green monkey kidney cells and the quantification of ZIKV using cell-based colorimetric immunodetection methods in 24-well and 96-well (high throughput) formats.

Abstract

Zika virus (ZIKV) is a mosquito-borne virus belonging to the genus Flavivirus. ZIKV infection has been associated with congenital brain abnormalities and potentially Guillain-Barré syndrome in adults. Research on ZIKV to understand the disease mechanisms is important to facilitate vaccine and treatment development. The method of quantifying viruses is crucial and fundamental in the field of virology. The focus forming assay (FFA) is a virus quantification assay that detects the viral antigen with antibodies and identifies the infection foci of cells using the peroxidase immunostaining technique. The current study describes the virus propagation and quantification protocol using both 24-well and 96-well (high throughput) formats. Compared with other similar studies, this protocol has further described foci size optimization, which can serve as a guide to expand the use of this assay for other viruses. Firstly, ZIKV propagation is performed in Vero cells for 3 days. The culture supernatant containing ZIKV is harvested and quantitated using the FFA. Briefly, the virus culture is inoculated onto Vero cells and incubated for 2-3 days. Foci formation is then determined after optimized staining processes, including cell fixation, permeabilization, blocking, antibody binding, and incubation with peroxidase substrate. The stained virus foci are visualized using a stereo microscope (manual counting in 24-well format) or software analyzer (automated counting in 96-well format). The FFA provides reproducible, relatively fast results (3-4 days) and is suitable to be used for different viruses, including non-plaque-forming viruses. Subsequently, this protocol is useful for the study of ZIKV infection and could be used to detect other clinically important viruses.

Introduction

Zika virus (ZIKV) infection is an emerging mosquito-borne viral disease. The first isolation of ZIKV was in Uganda in 1947¹^,²; it remained neglected from 1947 to 2007, as the clinical symptoms are most commonly asymptomatic and characterized by self-limiting febrile illness. In 2007, the Zika epidemic began in the Yap islands³^,⁴, followed by larger epidemics in the Pacific regions (French Polynesia, Easter Island, Cook Islands, and New Caledonia) from 2013 to 2014⁵^,⁶^,⁷^,⁸, where the severe neurological complication Guillain-Barré syndrome (GBS) was reported in adults for the first time⁹. During 2015 and 2016, the first widespread ZIKV epidemic swept across the Americas after the emergence of the Asian genotype of ZIKV in Brazil in as early as 2013¹⁰. During this outbreak, 440,000 to 1.3 million cases of microcephaly, and other neurological disorders, were reported in newborn babies¹¹. There is currently no specific cure or treatment for ZIKV infection; hence, there is an urgent medical need for ZIKV vaccines capable of preventing infections, particularly during pregnancy.

Virus quantification is a process to determine the number of viruses present in a sample. It plays an important role in research, and academic laboratories involve many fields, such as medicine and life sciences. This process is also important in commercial sectors, such as the production of viral vaccines, recombinant proteins, viral antigens, or antiviral agents. Many methods or assays can be used for virus quantification¹². The choice of methods or assays normally depends on the virus characteristics, desired level of accuracy, and the nature of the experiment or research. In general, methods of quantifying viruses can be divided into two categories: molecular assays that detect the presence of viral nucleic acid (DNA or RNA) and assays that measure virus infectivity in vitro¹². Quantitative polymerase chain reaction (qPCR, for DNA) or quantitative reverse transcription polymerase chain reaction (qRT-PCR, for RNA)¹³ and digital droplet PCR¹⁴ are examples of common molecular techniques used to quantitate the viral nucleic acid in a given sample¹⁵. However, these highly sensitive molecular techniques cannot differentiate between viable and non-viable viruses¹⁵. Therefore, research that requires information on biological features, such as virus infectivity on cells, cannot be completed using the abovementioned molecular techniques; assays that can measure and determine the presence of viable viruses are needed. Assays that measure virus infectivity include the plaque forming assay (PFA), 50% tissue culture infectious dose (TCID50), the fluorescent focus assay, and transmission electron microscopy (TEM)¹².

The PFA, developed by Renato Dulbecco in 1952, is one of the most commonly used methods for virus titration, including for ZIKV¹⁶. It is used to directly determine the viral concentrations for infectious lytic virions. The method is based on the ability of a lytic virus to produce cytopathic effects (CPEs; zones of cell death or plaques, an area of infection surrounded by uninfected cells) in an inoculated cell monolayer after viral infection. However, there are several drawbacks to the assay that affect its utility. The assay is time-consuming (takes approximately 7-10 days, depending on viruses), CPE-dependent, and prone to errors. In the present study, we report an immunocolorimetric technique, the focus forming assay (FFA), for detecting and quantifying ZIKV in 24-well plate and 96-well plate formats.

Protocol

1. Virus propagation

Cell preparation
1. Grow Vero cells in a 75 cm² cell culture flask containing 12 mL of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (see Table of Materials). Incubate the cells in a cell culture incubator at 37 °C with 5% CO₂.
2. Monitor the cells under a microscope; once the cells reach 70%-90% confluency, they are ready to be used (Figure 1A) .
  NOTE: The Vero cells double approximately every 24 h¹⁷. Dilutions of 1:10 should take 3 to 4 days to reach 80%-90% confluency in a 75 cm² flask. Monitor the cells daily or every other day.
Infection of the cell monolayer
1. Remove the growth medium from the cell culture flask using a 10 mL serological pipette. Rinse the flask with 3 mL of Dulbecco's phosphate buffered saline (dPBS) 2x using a 5 mL serological pipette.
  NOTE: A beaker with 10% sodium hypochlorite must be prepared to disinfect any discarded infectious liquid waste from flasks/plates.
2. Add 2 mL of serum-free DMEM (DMEM supplemented with 2 mM L-glutamine without FBS) and 20 µL of ZIKV inoculum into the cell culture flask. Incubate the flask with gentle rocking for 1 h at room temperature to allow virus adsorption.
  NOTE: Titration of the initial ZIKV stock will be helpful to determine the volume of ZIKV inoculum addition (step 2).
  CAUTION: ZIKV is classified as a biosafety level 2 (BSL-2) pathogen. All procedures with materials containing ZIKV must be conducted in a certiﬁed biosafety cabinet and follow all the laboratory standard operating procedures (SOPs) with appropriate personal protective equipment.
Addition of the overlay medium
1. After the 1 h incubation, remove and discard the diluted virus inoculum using a 5 mL serological pipette. Rinse the cell culture flask with 3 mL of dPBS 2x.
2. Add 12 mL of maintenance media (DMEM supplemented with 2% FBS, 2 mM L-glutamine, and 100 U/mL penicillin-streptomycin) into the cell culture flask to maintain the infected cells.
3. Incubate the infected Vero cells for 3 days in a cell culture incubator at 37 °C with 5% CO₂.
  NOTE: Monitor daily for the CPE of infected Vero cells under a microscope.
Harvesting of cell culture supernatant containing ZIKV
1. On day 3 post-infection, cell rounding and detachment (CPE) can be observed (Figure 1B-D). Harvest the cell culture supernatant containing the ZIKV into a 50 mL centrifuge tube using a 10 mL serological pipette.
2. Use a 0.22 µm Polyethersulfone syringe filter (see Table of Materials) to filter the cell culture supernatant. Aliquot 500 µL of the filtered cell culture supernatant into 2.0 mL screw cap tubes and store at -80 °C until further use.
  NOTE: Harvested ZIKV can be stored at -80 °C for long-term storage.
  CAUTION: Extra precautions must be taken if a syringe needle is used, as the needle can puncture the skin. Laboratory SOPs need to be established.

2. Virus quantification

Cell preparation
1. Seed Vero cells in designated plates (24-well plate: 0.5 mL/well, 7.5 x 10⁴ cells/well; 96-well plate: 0.1 mL/well, 1.5 x 10⁴ cells/well) and incubate the plate overnight in a cell culture incubator at 37 °C with 5% CO₂.
  NOTE: There are five different time points to be tested (24-well plate: 48 h, 60 h, 72 h, 84 h, and 96 h post-infection; 96-well plate: 24 h, 36 h, 48 h, 60 h, and 72 h post-infection); therefore, prepare one plate for each time point.
2. After the 24 h incubation and once the cells reach 70%-90% confluency (Figure 1E), the plate is ready for infection. Proceed to prepare the diluted virus stock (step 2.2) prior to infection of the cell monolayer.
Virus dilution
1. For 24- and 96-well plates, prepare six sterile 1.5 mL microcentrifuge tubes for each plate to carry out a tenfold dilution (10^-1 up to 10^-5), including a negative control. For the experiment setup for a 24-well plate, add 450 µL of serum-free DMEM into all six microcentrifuge tubes. For the experiment setup for a 96-well plate, add 135 µL of serum-free DMEM into six tubes.
  NOTE: Label each tube clearly to indicate the dilution of its contents before performing the tenfold serial dilution.
2. To perform serial dilution, for the 24-well plate experiment setup, add 50 µL of ZIKV stock that was harvested from step 1 into the 10^-1 tube that contains 450 µL of serum-free DMEM. For the 96-well plate experiment setup, add 15 µL of ZIKV stock into the 10^-1 tube that contains 135 µL of serum-free DMEM.
3. Vortex each tube to mix the virus and medium. This is the first tenfold dilution.
  NOTE: Proper mixing of virus and culture medium in each dilution tube is required to ensure accurate serial dilution.
4. For the 24-well plate experiment setup, use a fresh pipette tip to resuspend the 10^-1 tube and transfer 50 µL of diluted ZIKV into the 10^-2 tube as a second tenfold dilution. For the 96-well plate experiment setup, use a fresh pipette tip to resuspend the 10^-1 tube and transfer 15 µL of diluted ZIKV into the 10^-2 tube as a second tenfold dilution.
5. Repeat step 2.2.4 four times until the fifth tube (exclude negative control).
  NOTE: Use a fresh pipette tip after each pipetting step to avoid cross-contamination.
Infection of the cell monolayer
1. Remove and discard the conditioned medium from each well (24-well plate: 0.5 mL/well; 96-well plate: 0.1 mL/well).
2. Rinse each well with dPBS 2x (24-well plate: 300 µL/well; 96-well plate: 60 µL/well).
3. Working from the highest to the lowest dilution, add each serially diluted virus inoculum into the well (24-well plate: 200 µL/well; 96-well plate: 40 µL/well).
  NOTE: The infection of each dilution will be performed in duplicated wells. Maintain two uninfected wells as the negative control. Label the plate and wells clearly to avoid confusion. Change the pipette tips after each pipetting step to prevent cross-contamination.
4. Incubate the plate with gentle rocking for 1 h at room temperature to allow virus adsorption.
Addition of the overlay cell culture medium
1. After 1 h of incubation, remove and discard the virus suspension from the lowest concentration to the highest.
2. Wash the infected cells with dPBS 2x (24-well plate: 300 µL/well; 96-well plate: 60 µL/well).
3. Overlay the well with DMEM (supplemented with 2% FBS, 2 mM L-glutamine, and 100 U/mL penicillin-streptomycin) and 1.5% low viscosity carboxymethyl cellulose (CMC; see Table of Materials) (24-well plate: 1 mL/well; 96-well plate: 0.2 mL/well).
4. Incubate the plate in a cell culture incubator at 37 °C with 5% CO₂.
  NOTE: Do not disturb the plate during this incubation period.
5. Take the plate out from the cell culture incubator for staining at different time points (24-well plate: 48 h, 60 h, 72 h, 84 h, and 96 h post-infection; 96-well plate: 24 h, 36 h, 48 h, 60 h, and 72 h post-infection).

3. Staining

Cell fixation
1. After the specific hours of incubation (24-well plate: 48 h, 60 h, 72 h, 84 h, and 96 h post-infection; 96-well plate: 24 h, 36 h, 48 h, 60 h, and 72 h post-infection), remove and discard the overlay medium and wash the cells 3x with 1x PBS. For the 96-well plate, remove and discard the overlay medium and wash the cells 3x with 60 µL/well of 1x PBS with a multichannel pipette.
2. Add 4% paraformaldehyde to fix the cells (24-well plate: 300 µL/well; 96-well plate: 60 µL/well). Incubate the plate at room temperature for 20 min.
  CAUTION: Paraformaldehyde is a solid polymerized formaldehyde. It is a flammable, solid, white crystalline powder that releases formaldehyde gas when mixed with water or heated. All procedures involving the use of paraformaldehyde must be conducted in a certified chemical fume hood or approved exhausted enclosures following laboratory SOPs specific to formaldehyde-containing chemicals.
3. After 20 min, discard the paraformaldehyde and wash the cells 3x with 1x PBS. Perform permeabilization, blocking, and antibody incubations following steps 3.2-3.5.
  NOTE: When discarding 4% paraformaldehyde, follow the university or institute's waste disposal procedure.
Cell permeabilization
1. Add 1% octylphenoxy poly(ethyleneoxy)ethanol (see Table of Materials) to permeabilize the cells (24-well plate: 200 µL/well; 96-well plate: 40 µL/well). Incubate the plate at room temperature for 15 min.
2. After 15 min, discard the octylphenoxy poly(ethyleneoxy)ethanol and wash the cells 3x with 1x PBS.
Blocking
1. Add 3% skim milk to reduce the nonspecific binding in the sample (24-well plate: 500 µL/well; 96-well plate: 100 µL/well). Incubate the plate at room temperature for 2 h.
2. After 2 h, discard the 3% skim milk and wash the cells 3x with 1x PBS.
  NOTE: This is a stopping point. After adding 3% skim milk, the plates can be stored at 4 °C up to 2 days before primary antibody insertion.
Primary antibody incubation
1. Add anti-flavivirus monoclonal antibody, 4G2 (clone D1-4G2-4-15; primary antibody, see Table of Materials) diluted in 1% skim milk (1:1,000 ratio) (24-well plate: 200 µL/well; 96-well plate: 40 µL/well). Incubate the plate at 37 °C for 1 h.
2. After 1 h, remove the solution containing the monoclonal antibody and wash the cells 3x with 1x PBS.
Secondary antibody incubation
1. Add goat anti-mouse IgG secondary antibody conjugated with horseradish peroxidase (HRP) (see Table of Materials) diluted in 1% skim milk (1:1,000 ratio) (24-well plate: 200 µL/well; 96-well plate: 40 µL/well). Incubate the plates at 37 °C for 1 h.
2. After 1 h, remove the solution containing the secondary antibody and wash the cells 3x with 1x PBS.
Substrate incubation
1. Add 3,3'diaminobenzidine (DAB) peroxidase substrate (see Table of Materials) and incubate the plate for 30 min in the dark (24-well plate: 200 µL/well; 96-well plate: 40 µL/well). After 30 min, stop the reaction by washing the wells with water.
2. Air-dry the plates overnight and proceed to foci enumeration after the plates are completely dry.

4. Determination of the virus titer

Manual foci counting process (24-well format)
1. Foci can be visualized under a stereo microscope. Select the dilution that produces 50-200 foci.
2. Count the foci for each replicate of the selected dilution. Calculate the average number of foci for each of the selected dilutions.
3. Calculate the foci forming unit per mL (FFU/mL) for each sample with the formula below: FFU/mL = average number of foci counted/(dilution x volume of diluted virus added).
Automated foci counting process (96-well format)
1. Scan the 96-well plate on a commercial software analyzer.
  1. Double click on the software (see Table of Materials) to open.
  2. Click on Switch Suites and ensure that the suite is switched to any one that is applicable (Supplementary Figure 1A). Click OK.
  3. Begin the scan by clicking Scan > Full plate scan (Supplementary Figure 1B).
  4. Click on Dashboard to ensure the capture format is the 96-well format (Supplementary Figure 2A).
  5. Select the centering mode as "Auto Prealignment User Verified" (Supplementary Figure 2B).
  6. Click on Eject to load the plate.
    NOTE: Open the lid of the plate and place it upward with Row A at the top (Supplementary Figure 3A).
  7. Enter the plate name and click on OK. Click on Load to load the plate.
  8. Click on Start to start the scan. After that, calibrate the positions for A1, A12, and H1 using the buttons "Up, Down, Left, Right" and click on Confirm (Supplementary Figure 3B).
    NOTE: The software will start scanning each well.
  9. Once the scanning is complete, an overview image will pop up. Click on Close.
  10. Exit the scan by clicking on Back to switchboard.
2. Count the 96-well plate using the software.
  1. Click Count > Smart Count.
  2. On the software, it will show "Step 1 of 5: Select plates to count". Click on Load plate(s). Tick the whole folder and click on Select to import the scanned plate (Supplementary Figure 4A).
  3. On the software, it will show "Step 2 of 5: Define counting parameters". Click on Adjust parameters, and the parameters will be displayed (diffuse process; small/normal/large/largest/largest +1; spot separation; counted area; background balance; fiber removal; gating).
    NOTE: Start with one well, and check back and forth to find the best settings for all the wells.
  4. Once done, click on Next (Supplementary Figure 4B).
  5. On the software, it will show "Step 3 of 5: Select/unselect wells". Once the selection of the well to be counted is complete, click on Next to proceed.
    NOTE: The wells selected to be counted will appear with a "C" at the top right corner of each well (Supplementary Figure 5A).
  6. On the software, it will show "Step 4 of 5: Output Settings". Click on View/Modify Output Settings to check if the settings (such as image format) are suitable. Click on Save and Exit > Next (Supplementary Figure 5B).
  7. On the software, it will show "Step 5 of 5: Start AutoCount". Click on Start AutoCount (Supplementary Figure 6A).
  8. Once complete, click on Exit AutoCount.
Perform quality control (QC) in the commercial software analyzer.
1. On the switchboard page, click on Quality Control > Add plate(s). Tick the whole folder to import the counted plate, click on Select > Start QC (Supplementary Figure 6B).
2. Double-click on each well to audit the spots. Click on Count to remove any spots. The software will start counting.
  NOTE: Ensure that "Spots: Remove" is ticked. Completion of the counting can be indicated by the counted number of foci, for example "30" (Supplementary Figure 7A).
3. Once the counting ends (indicated by the counted number of foci, for example "30"), click "Yes" to remove spots (Supplementary Figure 7B). Triple left-click on the spot to be removed. Right-click to finish, then click on Yes.
4. Click on Finish Plate and Go to Project Overview once the QC is complete.
Perform imaging using the software analyzer.
1. Check the scanned, counted, and QC plate image (Figure 2).

Representative Results

ZIKV can be quantified using the FFA, as outlined schematically in Figure 3. For the 24-well plate, the infected Vero cells were fixed at 48 h, 60 h, 72 h, 84 h, and 96 h post-infection. The results showed that the cells remained intact (no cell detachment was observed) after 96 h (4 days) post-infection (Figure 4 and Supplementary Figure 8A-E). The appearance of virus foci was first observed at 48 h (2 days) post-infection (Figure 4A-F). However, the foci size was too small, making it difficult to count the foci accurately. The optimal foci size was achieved at 60 h (2.5 days) post-infection (Figure 4B). At the latter time points (72 h, 84 h, and 96 h post-infection), foci were larger and tended to merge or overlap. The merged or overlapped foci increased over time (Figure 4C-E). Therefore, foci formed at 60 h (2.5 days) after the infection were chosen to determine the ZIKV titer in a 24-well plate (Figure 4B).

For the 96-well plate, the infected Vero cells were fixed at 24 h, 36 h, 48 h, 60 h, and 72 h post-infection. The results showed that the cells remained intact after 72 h (3 days) post-infection (Figure 5A-F and Supplementary Figure 9A-E). The appearance of virus foci was first observed at 24 h (1 day) post-infection (Figure 5A). However, the foci size was too small up to 36 h (1.5 days) post-infection, making it difficult to accurately determine the number of foci (Figure 5A,B). The optimal foci size was achieved at 48 h (2 days) post-infection (Figure 5C). At the latter time points (60 h and 72 h post-infection), overlapped or merged foci were observed, and the number of the overlapped foci increased over time (Figure 5D,E). Therefore, foci formed at 48 h (2 days) after the infection were chosen to determine the virus titer of ZIKV isolates (Figure 5C). The foci formation can be visualized and enumerated using commercial software analyzers as an alternative.

Figure 1: Microscopic image of Vero cells. (A) Vero cells in 40x magnification showed70%-90% confluency in a 75 cm² cell culture flask for virus propagation. (B) CPE on Vero cells after being infected with ZIKV on day 1 post-infection at 100x magnification. (C) CPE on Vero cells after being infected with ZIKV on day 2 post-infection at 100x magnification. (D) CPE on Vero cells after being infected with ZIKV on day 3 post-infection at 100x magnification. (E) Vero cells at 40x magnification showed 70%-90% confluency in a 24-well plate after 24 h of incubation for virus quantification. Scale bar: 100 µm. Please click here to view a larger version of this figure.

Figure 2: Image of a 96-well format scanned, counted, and post-quality control plate using a commercial software analyzer. Please click here to view a larger version of this figure.

Figure 3: Workflow of staining for the foci forming assay. The staining processes including cell fixation, permeabilization, blocking, antibody binding, and incubation with peroxidase substrate. Please click here to view a larger version of this figure.

Figure 4: Foci forming assay for ZIKV P6-740 in 24-well plates at different time points. (A) Foci are less distinct on day 2 (48 h) post-infection. (B) Optimal foci size can be seen on day 2.5 (60 h) post-infection. (C–E) Foci have merged on day 3 (72 h), day 3.5 (84 h), and day 4 (96 h) post-infection. (F) Negative control of the plate. Scale bar: 1,000 µm. Please click here to view a larger version of this figure.

Figure 5: Foci forming assay for ZIKV P6-740 in 96-well plates at different time points. (A) Foci are less distinct to be counted on the commercial software analyzer on day 1 (24 h) post-infection. (B) Foci are less distinct to be counted on the commercial software analyzer on day 1.5 (36 h) post-infection. (C) Optimal foci size can be seen on day 2 (48 h) post-infection. (D,E) Foci have merged on day 2.5 (60 h) and day 3 (72 h) post-infection. (F) Negative control of the plate. Scale bar: 1,000 µm. Please click here to view a larger version of this figure.

Supplementary Figure 1: Screenshots of the startup page of the commercial software analyzer. (A) Switch the suite to any applicable one on the commercial software analyzer. Click "OK" once done. (B) To begin scanning on the commercial software analyzer, click "Scan" and then click "Full plate scan". Please click here to download this File.

Supplementary Figure 2: Screenshots to view "Capture format" and the selected centering mode as "Auto Prealignment User Verified" on the commercial software analyzer. (A) To view the capture format, click "Dashboard" and select the 96-well format as the capture format. (B) For centering mode, select "Auto Prealignment User Verified". Please click here to download this File.

Supplementary Figure 3: 96-well plate placement on the commercial software analyzer plate reader tray and a screenshot to calibrate the positions for wells A1, A12, and H1. (A) Place the plate upward with Row A at the top. (B) To calibrate the positions for wells A1, A12, and H1, use the buttons "Up, Down, Left, Right". Once done, click "Confirm". Please click here to download this File.

Supplementary Figure 4: Screenshots to select folders containing scanned plates for counting on the commercial software analyzer and "Step 2 of 5: Define counting parameters". (A) To count the scanned plates, click "Load plate(s)". Tick the whole folder and click "Select" to import the scanned plates. (B) Adjust the counting parameters. Click "Next" once the parameters are set. Please click here to download this File.

Supplementary Figure 5: Screenshots of the commercial software analyzer "Step 3 of 5: Select/unselect wells" and "Step 4 of 5: Output Settings". (A) Select and unselect the wells to be counted and click "Next" once done. (B) For output settings, click "View/Modify Output Settings" to check if the settings are suitable (e.g., image format). Click "Save and Exit" once done and then click "Next". Please click here to download this File.

Supplementary Figure 6: Screenshots of the commercial software analyzer "Step 5 of 5: Start AutoCount" and quality control page. (A) Once ready for plate counting, click "Start AutoCount". (B) On the quality control page, tick the whole folder to import the counted plate, click "Select", then click "Start QC". Please click here to download this File.

Supplementary Figure 7: Screenshots of the commercial software analyzer quality control page. (A) Double-click each well to audit spots. Click "Count" to remove any spot. Tick "Spots: Remove". (B) Triple left-click to remove spots. Right click to finish, then click "Yes". Please click here to download this File.

Supplementary Figure 8: Foci forming assay for ZIKV P6-740 in 24-well plates at different time points. A tenfold serial dilution (10^-1 to 10^-5) was performed on ZIKV P6-740 and infection was performed on Vero cells in duplicate, including a negative control. A raw data image was taken using a stereo microscope, with the scale bar indicating 1,000 µm. (A) Day 2 (48 h) post-infection. (B) Day 2.5 (60 h) post-infection. (C) Day 3 (72 h) post-infection. (D) Day 3.5 (84 h) post-infection. (E) Day 4 (96 h) post-infection. Please click here to download this File.

Supplementary Figure 9: Foci forming assay for ZIKV P6-740 in 96-well plates at different timepoints. A tenfold serial dilution (10^-1 to 10^-5) was performed on ZIKV P6-740 and infection was performed on Vero cells in duplicate, including a negative control. A raw data image was taken using a stereo microscope, with the scale bar indicating 1,000 µm. (A) Day 1 (24 h) post-infection. (B) Day 1.5 (36 h) post-infection. (C) Day 2 (48 h) post-infection. (D) Day 2.5 (60 h) post-infection. (E) Day 3 (72 h) post-infection. Please click here to download this File.

Discussion

There are several assays to determine virus titer; the PFA has a similar virus quantitation protocol as the FFA, in which the virus inoculum is diluted to allow individual plaques or foci to be distinguished. After staining, each plaque or foci indicates a single infectious particle in the inoculum¹⁹. The PFA is stained with crystal violet to visualize plaque formation caused by cell lysis or death. Hence, the PFA is more time-consuming, as it requires a longer time for the virus to cause CPEs, and it is only restricted to the viruses that induce cell lysis or death. Many laboratories have successfully used FFAs to determine infectious virus titers for flaviviruses, including ZIKV¹⁹^,²⁰^,²¹^,²²^,²³^,²⁴^,²⁵. The FFA is a cell-based colorimetric immunodetection method that detects the viral antigen with antibodies and, therefore, identifies the foci areas of infected cells using the immunostaining technique, but not plaques¹²^,²⁶. The FFA offers some advantages for ZIKV over the PFA. One clear advantage is that it is based on antibody recognition of viral components without discernable CPEs. In addition, using virus-specific antibodies is also useful in identifying different viruses or viral serotypes in mixed populations²⁷. Therefore, the FFA is more specific than the PFA as it measures all the virus infections and is not dependent on the viruses that cause enough cell death to form a visible plaque²⁸. The FFA also has a shorter incubation period than the PFA, which requires an obvious CPE that signifies cell lysis and death. Finally, using a 96-well plate, the FFA method provides the advantage of using more replicates and larger dilutions to detect and titrate the virus²⁷^,²⁹. In addition, the reported FFA assay can be easily adapted for virus neutralization tests and methods to screen for antiviral compounds. Incorporating commercial or free automated cell counting instruments or software can further improve the usability (consistency, accuracy, throughput) of the FFA and its associated methods.

When comparing the 24-well plate to the 96-well plate, it is important to note that the 24-well format requires a larger number of cells to be grown in monolayer cultures, as well as larger amounts of media and virus stock. As a result, the 24-well plate format may not be suitable for use with samples with limited volumes. This limitation can be overcome by using the 96-well format, as described in this paper. Firstly, the 96-well format requires less material, making it a more cost-effective option. Additionally, the automated counting of stained virus foci in the 96-well format allows high throughput and rapid analysis, which is not possible in the 24-well format, which requires manual counting. This automated counting process also increases the reproducibility and reduces subjectivity compared to manual counting, leading to more accurate and reliable results of the FFA. Therefore, the 96-well format with automated imaging systems is highly recommended for laboratories that require high throughput and reliable virus quantification.

On the other hand, some people use the immunofluorescent focus assay to detect ZIKV²⁵^,²⁷^,²⁸^,³⁰^,³¹. The immunofluorescence focus assay parallels the FFA, except that it is performed by immunostaining the antigens with fluorochrome-conjugated specific antibodies, followed by the counting of infection foci under a fluorescence microscope²⁵. This assay uses more costly reagents and needs fluorescence microscopy to complete the assay. Therefore, the immunofluorescence focus assay is limited to better-equipped laboratories, such as referral laboratories. It is not easy to use this assay in a resource-challenging setting.

Although the FFA has many advantages, it also has some limitations. Compared to other assays, such as the PFA, the FFA involves more steps during the staining processes. While the steps after fixation are flexible and allow for overnight or longer pauses, the staining of the foci still takes longer to complete. Furthermore, the FFA requires specific or cross-reacting antibodies in the staining process, which limits its applicability for identifying and quantifying new or novel viruses. Moreover, the cost of the FFA is higher compared to the PFA, which only requires crystal violet for staining. In addition to that, it is worth noting that the automated counting process (96-well format) can only be performed in a laboratory with the appropriate equipment; hence, it will be not suitable for laboratories without the necessary equipment.

In conclusion, we report detailed protocols for the propagation and quantification of ZIKV using the cell-based colorimetric immunodetection assay or the FFA in 24-well plate and 96-well plate formats. The method offers a number of practical advantages over the classical PFA. It is faster and amenable for high throughput applications when applied with an automated imaging system for foci counting. The standardization of reliable protocols for this study will greatly contribute to Zika research and can also be broadly adapted to quantify other clinically important viruses.

Divulgaciones

The authors have nothing to disclose.

Acknowledgements

This research received support from the Ministry of Higher Education Malaysia under the Long-Term Research Grant Scheme (LRGS MRUN Phase 1: LRGS MRUN/F1/01/2018) and funding for the Higher Institution Centre of Excellence (HICoE) program (MO002-2019). Figure 3 in this study that shows the workflow of staining for the foci forming assay is adapted from "DAB Immunohistochemistry" by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates/t-5f3edb2eb20ace00af8faed9-dab-immunohistochemistry.

Materials

0.22 µm Polyethersulfone syringe filter	Sartorius	S6534-FMOSK
1.5 mL microcentrifuge tube	Nest	615601
10 mL sterile serological pipette	Labserv	14955156
1x Dulbecco’s phosphate-buffered saline (dPBS)	Gibco	14190-136
2.0 mL Screw cap tube	Axygen	SCT-200-SS-C-S
24-well plate	Corning	3526
25 mL Sterile serological pipettes	Labserv	14955157
3,3'Diaminobenzidine (DAB) peroxidase substrate	Thermo Scientific	34065
37 °C incubator with 5% CO₂	Sanyo	MCO-18AIC
5 mL sterile serological pipette	Labserv	14955155
50 mL centrifuge tube	Falcon	LAB352070
75 cm² tissue culture flask	Corning	430725U
96-well plate	Falcon	353072
Anti-flavivirus monoclonal antibody, 4G2 (clone D1-4G2-4-15)	MilliporeSigma	MAB10216
Autoclaved 20x Phosphate buffered saline (PBS)	N/A	N/A	22.8 g of 8 mM Na₂HPO₄, 4.0 g of 1.5 mM KH₂PO₄, 160 g of 0.14 M NaCl, 4.0 g of 2.7 mM KCl, 1 L of MilliQ H₂O
Biological safety cabinet, Class II	Holten	HB2448
CTL S6 Universal ELISpot/FluoroSpot Analyzer	ImmunoSpot, Cellular Technology Limited (CTL)	CTL-S6UNV12	Commercial software analyzer
Dulbecco's Modified Eagle Medium (DMEM)	Gibco	12800-017
Fetal bovine serum (FBS)	Bovogen	SFBS
Goat anti-mouse IgG secondary antibody conjugated with horseradish peroxidase (HRP)	MilliporeSigma	12-349
Hemacytometer	Laboroptik LTD	Neubauer improved
IGEPAL CA-630 detergent	Sigma-Aldrich	I8896	Octylphenoxy poly(ethyleneoxy)ethanolIGEPAL
Inverted microscope	ZEISS	TELAVAL 31
Laboratory rocker	FINEPCR	CR300
L-Glutamine	Gibco	25030-081
Low viscosity carboxymethyl cellulose (CMC)	Sigma-Aldrich	C5678
Multichannel micropipette (10 – 100 µL)	Eppendorf	3125000036
Multichannel micropipette (30 – 300 µL)	Eppendorf	3125000052
Paraformaldehyde	Sigma-Aldrich	P6148
Penicillin-streptomycin	Gibco	15140-122
Single channel pipettes (10 – 100 µL)	Eppendorf	3123000047
Single channel pipettes (100 – 1000 µL)	Eppendorf	3123000063
Single channel pipettes (20 – 200 µL)	Eppendorf	3123000055
Skim milk	Sunlac Low Fat	N/A	Prepare 3% Skim milk in 1x PBS for blocking stage in staining
Sodium Hypochlorite	Clorox	N/A	To disinfect any discarded infectious liquid waste from flasks/plates
Stereomicroscope	Nikon	SMZ1000
Syringe disposable, Luer Lock, 10 mL with 21 G Needle	Terumo	SS10L21G
Vero African green monkey kidney cells	–	ECACC 88020401	Received from collaborator. However, Vero cells obtained from other suppliers should be able to be used with some optimization.

Referencias

Dick, G. W. A., Kitchen, S. F., Haddow, A. J. Zika virus. I. Isolations and serological specificity. Transactions of the Royal Society of Tropical Medicine and Hygiene. 46 (5), 509-520 (1952).
Dick, G. W. A., Kitchen, S. F., Haddow, A. J. Zika virus. II. Pathogenicity and physical properties. Transactions of the Royal Society of Tropical Medicine and Hygiene. 46 (5), (1952).
Duffy, M. R., et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. The New England Journal of Medicine. 360 (24), 2536-2543 (2009).
Musso, D., Nilles, E. J., Cao-Lormeau, V. M. Rapid spread of emerging Zika virus in the Pacific area. Clinical Microbiology and Infection. 20 (10), O595-O596 (2014).
Cao-Lormeau, V. -. M., et al. Zika virus, French polynesia, South pacific, 2013. Emerging Infectious Diseases. 20 (6), 1085-1086 (2014).
Dupont-Rouzeyrol, M., et al. Co-infection with Zika and dengue viruses in 2 patients, New Caledonia, 2014. Emerging Infectious Diseases. 21 (2), 381-382 (2015).
Roth, A., et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections-an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012-2014. Euro Surveillance. 19 (41), 20929 (2014).
Tognarelli, J., et al. A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014. Archives of Virology. 161 (3), 665-668 (2016).
Oehler, E., et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveillance. 19 (9), 20720 (2014).
Faria, N. R., et al. Zika virus in the Americas: early epidemiological and genetic findings. Science. 352 (6283), 345-349 (2016).
Rapid risk assessment: Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barré syndrome – 4th update. European Centre for Disease Prevention and Control Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-zika-virus-epidemic-americas-potential-association (2015)
Payne, S. Methods to study viruses. Viruses. , 37-52 (2017).
Bustin, S. A., Mueller, R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clinical Science. 109 (4), 365-379 (2005).
Sedlak, R. H., Jerome, K. R. Viral diagnostics in the era of digital polymerase chain reaction. Diagnostic Microbiology and Infectious Disease. 75 (1), 1-4 (2013).
Bae, H. -. G., Nitsche, A., Teichmann, A., Biel, S. S., Niedrig, M. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. Journal of Virological Methods. 110 (2), 185-191 (2003).
Dulbecco, R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proceedings of the National Academy of Sciences. 38 (8), 747-752 (1952).
Nahapetian, A. T., Thomas, J. N., Thilly, W. G. Optimization of environment for high density Vero cell culture: effect of dissolved oxygen and nutrient supply on cell growth and changes in metabolites. Journal of Cell Science. 81, 65-103 (1986).
Agbulos, D. S., Barelli, L., Giordano, B. V., Hunter, F. F. Zika virus: quantification, propagation, detection, and storage. Current Protocols in Microbiology. 43, (2016).
Brien, J. D., Lazear, H. M., Diamond, M. S. Propagation, quantification, detection, and storage of West Nile virus. Current Protocols in Microbiology. 31, (2013).
Bolívar-Marin, S., Bosch, I., Narváez, C. F. Combination of the focus-forming assay and digital automated imaging analysis for the detection of dengue and Zika viral loads in cultures and acute disease. Journal of Tropical Medicine. 2022, 2177183 (2022).
Dangsagul, W., et al. Zika virus isolation, propagation, and quantification using multiple methods. PLoS One. 16 (7), e0255314 (2021).
Brien, J. D., et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. Journal of Virology. 84 (20), 10630-10643 (2010).
Lazear, H. M., et al. A mouse model of Zika virus pathogenesis. Cell Host & Microbe. 19 (5), 720-730 (2016).
Miner, J. J., et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell. 165 (5), 1081-1091 (2016).
Kang, W., Shin, E. -. C. Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions. PLoS One. 7 (8), e43960 (2012).
Brien, J. D., et al. Isolation and quantification of Zika virus from multiple organs in a mouse. Journal of VIsualized Experiments. (150), e59632 (2019).
Payne, A. F., Binduga-Gajewska, I., Kauffman, E. B., Kramer, L. D. Quantitation of flaviviruses by fluorescent focus assay. Journal of Virological Methods. 134 (1-2), 183-189 (2006).
Moser, L. A., et al. Growth and adaptation of Zika virus in mammalian and mosquito cells. PLoS Neglected Tropical Diseases. 12 (11), e0006880 (2018).
Ishimine, T., Tadano, M., Fukunaga, T., Okuno, Y. An improved micromethod for infectivity assays and neutralization tests of dengue viruses. Biken Journal. 30 (2), 39-44 (1987).
Leiva, S., et al. Application of quantitative immunofluorescence assays to analyze the expression of cell contact proteins during Zika virus infections. Virus Research. 304, 198544 (2021).
Lee, E. M., Titus, S. A., Xu, M., Tang, H., Zheng, W. High-throughput Zika viral titer assay for rapid screening of antiviral drugs. ASSAY and Drug Development Technologies. 17 (3), 128-139 (2019).

Play Video

PDF

DOI

DOWNLOAD MATERIALS LIST

Citar este artículo

Tan, J., Wong, J., Zainal, N., AbuBakar, S., Tan, K. Virus Propagation and Cell-Based Colorimetric Quantification. J. Vis. Exp. (194), e64578, doi:10.3791/64578 (2023).